Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16786
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNorth, Andrea J-
dc.contributor.authorKaras, John A-
dc.contributor.authorMa, Michelle T-
dc.contributor.authorBlower, Philip J-
dc.contributor.authorAckermann, Uwe-
dc.contributor.authorWhite, Jonathan M-
dc.contributor.authorDonnelly, Paul S-
dc.date2017-08-02-
dc.date.accessioned2017-08-10T01:24:00Z-
dc.date.available2017-08-10T01:24:00Z-
dc.date.issued2017-08-21-
dc.identifier.citationInorganic Chemistry 2017; 56(16): 9725-9741en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16786-
dc.description.abstractThis research aimed to develop new tumor targeted theranostic agents taking advantage of the similarities in coordination chemistry between technetium and rhenium. A γ-emitting radioactive isotope of technetium is commonly used in diagnostic imaging, and there are two β- emitting radioactive isotopes of rhenium that have the potential to be of use in radiotherapy. Variants of the 6-hydrazinonicotinamide (HYNIC) bifunctional ligands have been prepared by appending thioamide functional groups to 6-hydrazinonicotinamide to form pyridylthiosemicarbazide ligands (SHYNIC). The new bidentate ligands were conjugated to the tumor targeting peptides Tyr3-octreotate and cyclic-RGD. The new ligands and conjugates were used to prepare well-defined {M═O}3+ complexes (where M = 99mTc or natRe or 188Re) that feature two targeting peptides attached to the single metal ion. These new SHYNIC ligands are capable of forming well-defined rhenium and technetium complexes and offer the possibility of using the 99mTc imaging and 188/186Re therapeutic matched pairs.en_US
dc.titleRhenium and technetium-oxo complexes with thioamide derivatives of pyridylhydrazine bifunctional chelators conjugated to the tumour targeting peptides octreotate and cyclic-RGDfKen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInorganic Chemistryen_US
dc.identifier.affiliationThe School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Victorria, Australiaen_US
dc.identifier.affiliationDivision of Imaging Sciences and Biomedical Engineering, King’s College London, St Thomas’ Hospital, London, UKen_US
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28766938en_US
dc.identifier.doi10.1021/acs.inorgchem.7b01247en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-0707-6257en_US
dc.identifier.orcid0000-0002-3349-7346en_US
dc.identifier.orcid0000-0001-5373-0080en_US
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 3, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.